SANUWAVE Health to Showcase its Shock Wave Technology at the 2015 Biofilm Science and Technology Meeting
GlobeNewswire - Wed Jul 08, 8:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading shock wave technology company, today announced that the Company will have poster presentations and a laboratory demonstration of its patented shock wave technology at the Center for Biofilm Engineering's 2015 Biofilm Science and Technology Meeting held at Montana State University in Bozeman, Montana on July 13-16, 2015.
SANUWAVE Health Provides an Update on the dermaPACE Clinical Trial
GlobeNewswire - Tue Jun 30, 7:00AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced the plan for completing the Company's Phase III supplemental clinical trial that used the dermaPACE for treating diabetic foot ulcers.
SANUWAVE Health to Present at the 2015 Landmark Venture Forum
GlobeNewswire - Mon Jun 29, 3:30PM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), a shockwave technology company, announced today that Kevin A. Richardson II, SANUWAVE's Chairman of the board and Chief Executive Officer, will present at the 2015 Landmark Venture Forum, hosted by Landmark Angels, Inc., being held Tuesday, June 30 at the offices of Marcum LLP in Boston MA.
SANUWAVE Health to Hold dermaPACE Clinical Trial Update Conference Call on Tuesday, June 30, 2015
GlobeNewswire - Thu Jun 25, 4:00PM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) announced today that the Company will release an update on the Phase III supplemental clinical trial using the dermaPACE for treating diabetic foot ulcers on June 30, 2015.
SANUWAVE Announces Strengthening of Balance Sheet With Amendment and Extension of Promissory Notes
GlobeNewswire - Thu Jun 18, 8:05AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced it has entered into an amendment to certain provisions of the two promissory notes dated August 1, 2005 between the Company and HealthTronics, Inc. with an aggregate outstanding principal balance of $5,372,743.
SANUWAVE Health to Present at Upcoming Financial Conferences
GlobeNewswire - Thu May 14, 7:30AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), today announced the Company's upcoming financial conferences schedule:
SANUWAVE Health's (SNWV) CEO Kevin Richardson on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun May 10, 4:36AM CDT
SANUWAVE Health reports Q1 results
Seeking Alpha - at Seeking Alpha - Wed May 06, 4:26PM CDT
SANUWAVE Health Reports First Quarter Financial Results and Provides a Business Update
GlobeNewswire - Wed May 06, 4:00PM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV), today reported financial results for the three months ended March 31, 2015 and provided a business update. The Company will host a conference call tomorrow, May 7, 2015, at 10:00 a.m. Eastern Time.
SANUWAVE Health to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 7, 2015
GlobeNewswire - Mon May 04, 3:30PM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) announced today that the Company will release financial results for the first quarter ended March 31, 2015, after the markets close on May 6, 2015.
OTC Daily Alert Stock Watch - SANUWAVE Health, Inc (OTC: SNWV)
WorldStockWire - Mon Dec 15, 2:00AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
SANUWAVE Health Signs Memoranda of Understanding With Dasman Diabetes Institute and Kuwait Life Sciences Company
GlobeNewswire - Tue Dec 02, 7:39AM CST
Companies to Establish a Strategic Alliance and Joint Venture to Introduce the dermaPACE Device as a Preferred Treatment for Diabetic Foot Ulcers in the Gulf Cooperation Council Region
SANUWAVE Enrolls 130th Patient in Its dermaPACE Clinical Trial Treating Diabetic Foot Ulcers
GlobeNewswire - Mon Dec 01, 7:30AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the Company has enrolled its 130 patient in the Phase III supplemental clinical trial using dermaPACE for treating diabetic foot ulcers (DFU's), which represents the number of patients the Company must enroll for the second interim analysis by the independent Data Monitoring Committee (DMC). The Company has suspended further enrollment in the study until the Data Monitoring Committee provides feedback on the 130 patients.
SANUWAVE Health Reports Third Quarter Financial Results and Provides a Business Update
GlobeNewswire - Wed Nov 12, 4:13PM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) today reported financial results for the three and nine months ended September 30, 2014 and provided a business update. The Company will host a conference call on Thursday, November 13, 2014, at 10:00 a.m. Eastern Time.
SANUWAVE Health to Hold Third Quarter 2014 Financial Results Conference Call on Thursday, November 13
GlobeNewswire - Thu Nov 06, 7:42AM CST
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the Company will release financial results for the third quarter ended September 30, 2014 after the markets close on November 12, 2014.
SANUWAVE Health Receives Information From the Data Monitoring Committee on the dermaPACE Clinical Trial
GlobeNewswire - Wed Sep 10, 7:30AM CDT
SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the independent Data Monitoring Committee (DMC) has performed an interim analysis on the efficacy results for the first 90 patients in the Phase III supplemental clinical trial using the dermaPACE for treating diabetic foot ulcers. The DMC has recommended the Company continue enrollment of patients into the study up to the next predefined patient analysis point of 130 patients. The Company has continued to enroll patients while waiting on the 12 week efficacy analysis for the first 90 patients and expects to complete enrollment for the 130 patients by October 31, 2014.